Introduction
============

Adalimumab (ADA) has been shown to be safe and effective in polyarticular juvenile idiopathic arthritis (pJIA), and is approved for use in moderate to severe pJIA patients (pts) ≥4 years (yrs) in the US, Australia, and Japan, and in the EU for pts ≥2 yrs.

Objectives
==========

This *post hoc* report describes the observed use of vaccines in pJIA pts receiving ADA in 3 clinical trials and one registry.

Methods
=======

Pts with active pJIA were enrolled in one of the following trials: M10-444 (ages 2 to \<4 or ≥4 weighing \<15 kg in US, EU), M10-240 (ages 4-17 in Japan), DE038 (ages 4-17 in US, EU) or the STRIVE (P10-262) registry (ages 4-17 in US, EU, and Australia). Pts received ADA±methotrexate. Vaccinations were administered based on the judgment of the study investigator or the treating physician. Descriptive statistics were used to summarize all vaccinations. Adverse events (AEs) related to active influenza virus infection events occurring within 270 days after influenza vaccination were collected by a predefined MedDRA query 15.1 \[Lack of efficacy/effect Influenza (Vaccination Product Specific)\].

Results
=======

The influenza vaccine was the most frequently administered: 55, 63, 10 and 22 influenza vaccines were administered in DE038, M10-240, M10-444 and P10-262, respectively. In addition, pneumococcal, human papilloma virus, diphtheria, tetanus and/or pertussis, hepatitis A and B, and polio vaccines were administered. 2 pts each received \>5 vaccinations in DE038 and M10-240, while 3 pts each in M10-444 and P10-262 received \>1 but \<5 vaccinations. The influenza vaccine was administered to 32/171 (19%), 20/25 (80%), 6/32 (19%) and 21/533 (4%) of pts during the course of the study in DE038, M10-240, M10-444 and P10-262 respectively, and the mean (SD) time to 1st influenza vaccination while pts were on ADA was high: 675 (618), 189 (80), 93 (90) and 443 (396) days. The rates of influenza-related AEs reported for pts who received influenza vaccinations and those who did not were: 13% vs 9% for DE038, 15% vs 20% for M10-240, 0% vs 12% for M10-444, and 5% vs 0.4% for P10-262. Table [1](#T1){ref-type="table"}.

  All Vaccinations                           DE038        M10-240      M10-444     P10-262
  ------------------------------------------ ------------ ------------ ----------- ------------
  Total patients vaccinated, n/N             38/171       20/25        6/32        22/533
                                                                                   
  Mean age, yrs (SD)                         11.8 (3.6)   13.6 (3.3)   3.0 (0.7)   12.7 (4.0)
                                                                                   
  Total vaccinations, n                      77           64           10          25
                                                                                   
  Patients with \>1 type of vaccination, n   11           1            0           2
                                                                                   
  Different types of vaccinations, n         9            2            1           4
                                                                                   
  Mean time to 1^st^ vaccination\*, days     688          189          93          448
                                                                                   
  Mean age at 1^st^ vaccination\*, yrs       12.9         14.0         3.6         12.0

^\*while\ on\ ADA^

Conclusion
==========

These data support the idea that pJIA pts treated with ADA can be immunized with routine, inactive, preventative vaccines. Not all of the eligible pts were vaccinated on time according to the Centers of Disease Control (CDC) recommendations, and many pts were not vaccinated at all, suggesting that physicians may be reluctant to use vaccines in children receiving antirheumatic therapies. Further investigation of vaccination practices for pts with JIA is warranted.
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